Drug Database
Back to search

United States· US:10702-223_5462a6ca-39eb-3b07-e063-6394a90a9020

Atovaquone Oral Suspension

A atovaquone product containing atovaquone, registered in United States by KVK-Tech, Inc.. The same ATC class is registered in 11 of our 19 countries.

ATC P01AX06

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedAtovaquone Oral SuspensionATCP01AX06REGISTER NO.US:10702-223_5462a6ca…PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about atovaquoneAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Atovaquone is registered in 11 of 19 countries.

Countries holding a registration under ATC P01AX06 (atovaquone), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 5 of them publish a price we can compare per daily dose
Search atovaquone products by name

Atovaquone · ATC P01AX06

11 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Franceprice
  • Germany
  • Netherlands
  • Norwayprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
ATOVAQUONE
Manufacturer
KVK-Tech, Inc.
Country
United States (US)
ATC code
P01AX06
ATC class
Atovaquone
Defined daily dose
1.5 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 1

  • ndc11
    10702-223-21

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

182 interactions on record for atovaquone.

Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check atovaquone against other medicinesHow interaction checks work

Atovaquone · interactions on record

182 records

  • 8 severe
  • 32 moderate
  • 4 minor
  • 133 info

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • EfavirenzJ05AG03severe
  • PexidartinibL01EX15severe

5 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Atovaquone in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All atovaquone products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Belgium · Wellvone
  • Germany · Atovaquon Glenmark, Wellvone
  • Denmark · Atovaquone Glenmark
  • Spain · Atovacuona Glenmark, Wellvone
  • France · Atovaquone Biogaran, Wellvone
  • United Kingdom (Northern Ireland) · Atovaquone Amarox, Atovaquone Glenmark Pharmaceuticals Europe
  • Greece · Atovaquone Vocate, Wellvone
  • Italy · Atovaquone Glenmark, Wellvone
  • Luxembourg · Wellvone
  • Netherlands · Atovaquon Glenmark, Wellvone
  • Norway · Atovaquone Glenmark
  • Portugal · Atovaquona Kabi, Wellvone
  • Sweden · Atovaquone Glenmark, Wellvone

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d58bf178-616e-4401-8445-661f54a9e9b5
GET /v1/drugs/d58bf178-616e-4401-8445-661f54a9e9b5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "750",
  "substance": "ATOVAQUONE",
  "productndc": "10702-223",
  "dosage_form": "SUSPENSION",
  "dea_schedule": null,
  "strength_unit": "mg/5mL",
  "application_number": "ANDA210510",
  "marketing_category": "ANDA"
}
API referenceMCP serverPlans

See everything about atovaquone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console